Heparin-like biomacromolecules (HepLBm), exhibiting similar chemical structure and
biological properties to
heparin, can be obtained by modifying either synthetic
biopolymers or natural biomacromolecules with physical or chemical methods. In this work, a low-cost and biocompatible
sodium alginate was chosen as a model biomacromolecule to design
anticoagulant HepLBm with a similar sulfation degree to
heparin. FTIR, 1H NMR, and
element analysis data were used to confirm the chemical structure of HepLBm.
Hemolysis tests, clotting time, complement activation, and contact activation tests were carried out to determine the in vitro
anticoagulant activity of HepLBm. In addition, systematic studies of blood cell count, coagulation function, and histopathology were performed to demonstrate the in vivo
anticoagulant activity and toxicity of HepLBm with SD rat experiments. Furthermore, a series of linear molecules containing carboxyl groups, sulfonic groups, and
hydroxyl groups were selected and their clotting time was tested to provide a mechanism analysis for the excellent
anticoagulant activity of HepLBm. With the excellent in vitro/in vivo
anticoagulant activity, good biocompatibility, and low cost, the HepLBm synthesized in this work would have great potential for substitution of
heparin in many application fields, such as the surface modification of biomedical devices, extracorporeal
anticoagulants, and other clinical fields.